The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: An analysis of residual risk attributable to lipid profile in acute coronary syndrome.;Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo

Endocrinologia y Nutricion

Volumn 58, Issue 1, 2011, Pages 38-47

  Millán Núnez Cortes, Jesús ^a   Montoya, Juan Pedro Botet ^b   Salas, Xavier Pintó ^c   Mijares, Antonio Hernández ^d   Carey, Vincent J ^e   Hermans, Michel P ^f   Sacks, Frank M ^g   Fruchart, Jean Charles ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e CHANNING LABORATORY   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIV LILLE   (France)

Author keywords

Dyslipidemia; Ischemic heart disease; Residual risk

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; HEALTH CARE ORGANIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INTERNATIONAL COOPERATION; LIPIDS; MALE; MEDICAL RECORDS; META-ANALYSIS AS TOPIC; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT;

EID: 79251611466     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.10.004     Document Type: Article

References (54)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-421.
2. European guidelines on cardiovascular disease prevention in clinical practice. Executive summary. EHJ. 2007, 28:2375-2414. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
3. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006, 113:236-272.
4. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126. American Diabetes Association.
5. Standards of medical care in diabetes-2008. Diabetes Care. 2008, 31:S12-S54. American Diabetes Association.
6. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J. 2007, 28:88-136.
7. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
8. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996, 335:1001-1009.
10. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation. 2000, 102:1893-1900.
11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet. 2002, 360:7-22. Heart Protection Study Collaborative Group.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
13. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003, 361:1149-1158.
14. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995, 333:1301-1307.
15. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998, 279:1615-1622.
16. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002, 360:1623-1630.
17. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
18. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005, 366:1267-1278.
19. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371:117-125. Cholesterol Treatment Trialists' (CTT) Collaborators.
20. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-1504.
21. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352:1425-1435.
22. Ravnskov U., Rosch P.J., Sutter M.C., Houston M.C. Should we lower cholesterol as much as possible?. BMJ. 2006, 332:1330-1332.
23. Waters D.D. Safety of high-dose atorvastatin therapy. Am J Cardiol. 2005, 96(Suppl 1):69-75.
24. Armitage J. The safety of statins in clinical practice. Lancet. 2007, 370:1781-1790.
25. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003, 163:553-564.
26. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006, 355:549-559.
27. Stanek E.J., Sarawate C., Willey V.J., Charland S.L., Cziraky M.J. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin. 2007, 23:553-563.
28. Hayward R.A., Hofer T.P., Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006, 145:520-530.
29. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004, 364:937-952.
30. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., Ahearn D., Kuvin J.T., Karas R.H. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary high disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007, 100:1499-1501.
31. Ferrières J., Elbaz M., Maupas E., Carriè D., Puel J. Inadequate management of dyslipidaemic patients in France. Results of the Odyssée study. Arch Mal Coeur. 2004, 97:187-193.
32. Carroll M.D., Lacher D.A., Sorlie P.D., Cleeman J.I., Gordon D.J., Wolz M., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005, 294:1773-1781.
33. Sarawate C.A., Cziraky M.J., Stanek E.J., Willey V.J., Corbelli J.C., Charland S.L. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?. Clin Ther. 2007, 29:196-209.
34. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007, 298:309-316.
35. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007, 297:299-308.
36. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977, 62:707-714.
37. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROCAM Study. Circulation. 2002, 105:310-315.
38. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989, 79:8-15.
39. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2001, 104:1108-1113.
40. Weverling-Rijnsburger A.W.E., Jonkers I.J.A.M., van Exel E., Gussekloo J., Westendorp R.G.J. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med. 2003, 163:1549-1554.
41. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007, 115:450-458.
42. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992, 70:733-737.
43. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996, 77:1179-1184.
44. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992, 85:37-45.
45. Arca M., Montali A., Valiante S., Campagna F., Pigna G., Paoletti V., et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol. 2007, 100:1511-1516.
46. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004, 109:42-46.
47. Sacks F.M., Tonkin A.M., Craven T., Pfeffer M.A., Shepherd J., Keech A., et al. Coronary heart disease in patients with low LDL-cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002, 105:1424-1428.
48. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007, 357:1301-1310.
49. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008, 51:724-730.
50. Bruckert E., Baccara-Dinet M., Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med. 2007, 24:388-391.
51. Goldenberg I., Benderly M., Sidi R., Boyko V., Tenenbaum A., Tanne D., et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 2009, 103:41-45.
52. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366:1849-1861.
53. Tonkin A.M., Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010, 122:850-852.
54. Fruchart J.C., Sacks F.M., Hermans M.P. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010, 26:1793-1797. International Steering Committee of R(3)i.